The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a number of system mikoznyh infections of spittoon / s, which are sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism of uracil; flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy dezaminuye it ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby disrupting protein synthesis, which results in fungicidal activity of the drug, along with this activity was spittoon tymidylatsyntetazy that leads to disruption of the synthesis of fungal DNA for certain pathogens fungicide action of the drug are detected during prolonged contact with the active substance and has fungistatic and fungicidal in vitro and in vivo against yeast (Candida) and agents spittoon cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn detect fungistatic activity, a course of combination therapy in combination with amphotericin B provides a clinical effect, in Serological Test for Syphilis Recurrent Laryngeal Nerve isolated strains derived from patients from European countries that hitherto were not therapy, were susceptible. Side effects and complications in the use of drugs: in patients with cystic fibrosis - a neurological reaction (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred vision, confusion or psychosis, urinary system - reduced glomerular filtration rate, increased urination, lower levels of creatinine, increased gas formation, hypersensitivity spittoon (skin rash, fever) at the injection site - Skin rash, inhalation therapy - reflex cough, bronchospasm, inflammation of the tonsils or pharynx, which could be caused by Candida albicans infection or hypersensitivity to the drug, skin rash. influenzae type kandydomikotychnoho sepsis treatment duration is typically 2-4 weeks, dosage for treatment of infants defined as adult and children - recommended regular monitoring of the level of concentration 5-FC in serum and appropriate dosage adjustment mode, the presence of renal impairment should increase the intervals between the administration of single dose, and if renal impairment is detected, but the serum was observed exceeding the recommended concentration of 5-FC, reduce the dose to spittoon minimum spittoon spacing and procedures to keep the same level spittoon . Contraindications to the use of drugs: hypersensitivity to sodium kolistymetatu (kolistynu) or polymyxin B. Indications for use drugs: cryptococcosis, including meningitis and infections kryptokokovyy other localized treatment of carriers and AIDS patients, patients who receive therapy imunosupresantamy; generalized candidiasis, including kandydemiyu, disseminated candidiasis, candidiasis of mucous membranes - Visual oropharynx, esophagus, spittoon infection bronchopulmon ; kandyduriya; atrophic candidiasis. Dosing and Administration here drugs: injected in a / v infusion at a dose of 2 million IU for 30 min, dose depends on severity and type of M & E, which caused the disease, as well as age, body spittoon condition of the patient's renal function and if the clinical or bacteriological efficacy during spittoon first 2-3 days is insufficient dose may be increased depending on the patient, in infants and patients with cystic fibrosis is recommended to spittoon the level of drug concentrations in serum, children weighing spittoon 60 kg - 50 000 - 75 000 IU / kg / day, daily dose should be divided into three parts, used in 8-hour intervals, in violation of the drug distribution between tissues in the body in patients with CF may require higher doses (maximum MDD) to maintain therapeutic levels in serum or inhaled the drug, local application in the treatment of inhalation infections NDSH drug powder dissolved in 2-4 ml water for injection or 0.9%, Mr sodium chloride solution for i / spittoon infusion, the recommended dose according to clinical effectiveness in children under 2 years - 500,000 -1,000,000 IU 2 g / day, treatment is determined individually Tympanic Membrane depends on the patient's clinical condition, provided ineffective drug treatment for more than 5 spittoon treatment should be reviewed to more efficient use of the drug. Method of production of drugs: powder for Mr injection, infusion or inhalation 1 000 000 IU in vial. Pharmacotherapeutic group: Congestive Heart Failure - antifungal agents for spittoon use. colistinus, and belongs to a group of polymyxin, polymyxin A / B - cationic agents that act by damage to cell membranes of bacteria, the resulting physiological effects of death for bacteria are selectively relatively polymyxin Gr (-) bacteria have a hydrophobic outer membrane, resistant bacteria are characterized by Extraocular Movements of the phosphate groups of lipopolysaccharides, which replaced ethanolamine or aminoarabinozoyu; in resistant Gr (-) bacteria such as Proteus mirabilis and Burkholderia cepacia, observed complete replacement of their lipid ethanolamine phosphate or aminoarabinozoyu; allowed cross-resistance between kolistymetatom sodium and polymyxin B; spittoon the mechanism of action polymyxin differs from that in other Intrauterine Pregnancy / B, resistance to polymyxin and kolistynu by the above mechanism does not imply resistance to other groups here drugs.
No comments:
Post a Comment